Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...

Novo won the U.S. Food and Drug Administration's approval in 2024 to use Wegovy to reduce the risk of cardiovascular death, ...

Robbie Williams' concerns over weight-loss injections potentially harming his eyesight have sparked widespread worry. While ...

The results from the two trials of early-stage Alzheimer's patients, called EVOKE and EVOKE+, are another setback for the ...

Novo's upcoming Alzheimer's trial results will test whether Rybelsus can slow cognitive decline and reshape treatment ...

The oral version of Rybelsus failed to meet its primary goal in two late-stage clinical trials, which aimed to evaluate its ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.